Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that pricing information for Ryoncil® is now available in all four ...

DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Mesoblast Limited ( ($AU:MSB) ) has provided an announcement. Mesoblast Limited announced that its CEO, Silviu Itescu, will ...

Mesoblast's RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal ...

Regenerative medicine, a rapidly advancing field, can be generally defined as a therapeutic methodology for the repair, ...

Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...

Regenerative medicine company Mesoblast Ltd. is preparing to launch its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil, (remestemcel-L), in March in the U.S. and has ...

Mesoblast Limited (NASDAQ:MESO) is set to release its quarterly earnings with an estimated EPS of -$0.25 and revenue of approximately $2.39 million. The U.S. launch of Ryoncil® is expected to ...

Dr Silviu Itescu, Chief Executive of Mesoblast, said: Our FDA approved product Ryoncil will be available in the coming weeks to the children with SRaGvHD in need of life-saving therapy.

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ...